Ono Nets 5.8% Revenue Growth in FY2020 on Opdivo, Forxiga

Ono Pharmaceutical on May 11 reported growth of 5.8% in its FY2020 consolidated revenue to reel in 309.2 billion yen on the back of brisk sales of the anti-PD-1 antibody Opdivo (nivolumab) and the SGLT2 inhibitor Forxiga (dapagliflozin). In the...read more